Safety, efficacy, and patient acceptability of imiquimod for topical treatment of actinic keratoses

Figures & data

Table 1 Imiquimod formulations, indications, and dosing regimens

Imiquimod formulation	Indication	Dosing regimen
5% cream, topical	Treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults; restricted to an area of skin totaling 25 cm^2	2 times per week for up to 16 weeks
3.75% cream, topical	Treatment of clinically typical, visible, or palpable actinic keratoses on the full face or balding scalp	Daily use for 2 weeks, followed by 2 weeks of nontreatment, followed by 2 weeks of daily use for a total of 6 weeks

Figure 1 Chemical structure of Imiquimod.

Figure 2 Mechanism of Imiquimod.

Figure 3 Characteristic patient response during a course of imiquimod therapy for actinic keratoses.